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Hospital revisits within 30 days after discharge for medical 
 conditions targeted by the Hospital Readmissions Reduction 
 Program in the United States: national retrospective analysis
Rishi K Wadhera,1 Karen E Joynt Maddox,2 Dhruv S Kazi,1 Changyu Shen,1 Robert W Yeh1 
AbstrAct
Objective
To determine any changes in total hospital revisits 
within 30 days of discharge after a hospital stay 
for medical conditions targeted by the Hospital 




Hospital stays among Medicare patients for heart 
failure, acute myocardial infarction, or pneumonia 
between 1 January 2012 and 1 October 2015.
ParticiPants
Medicare fee-for-service patients aged 65 or over.
Main OutcOMes
Total hospital revisits within 30 days of discharge 
after hospital stays for medical conditions targeted by 
the HRRP, and by type of revisit: treat-and-discharge 
visit to an emergency department, observation stay 
(not leading to inpatient readmission), and inpatient 
readmission. Patient subgroups (age, sex, race) were 
also evaluated for each type of revisit.
results
Our study cohort included 3 038 740 total index 
hospital stays from January 2012 to September 
2015: 1 357 620 for heart failure, 634 795 for acute 
myocardial infarction, and 1 046 325 for pneumonia. 
Counting all revisits after discharge, the total number 
of hospital revisits per 100 patient discharges for 
target conditions increased across the study period 
(monthly increase 0.023 visits per 100 patient 
discharges (95% confidence interval 0.010 to 0.035)). 
This change was due to monthly increases in treat-
and-discharge visits to an emergency department 
(0.023 (0.015 to 0.032) and observation stays (0.022 
(0.020 to 0.025)), which were only partly offset 
by declines in readmissions (−0.023 (−0.035 to 
−0.012)). Increases in observation stay use were more 
pronounced among non-white patients than white 
patients. No significant change was seen in mortality 
within 30 days of discharge for target conditions 
(−0.0034 (−0.012 to 0.0054)).
cOnclusiOns
In the United States, total hospital revisits within 30 
days of discharge for conditions targeted by the HRRP 
increased across the study period. This increase was 
due to a rise in post-discharge emergency department 
visits and observation stays, which exceeded the 
decline in readmissions. Although reductions in 
readmissions have been attributed to improvements 
in discharge planning and care transitions, our 
findings suggest that these declines could instead 
be because hospitals and clinicians have intensified 
efforts to treat patients who return to a hospital within 
30 days of discharge in emergency departments and 
as observation stays.
Introduction
Healthcare systems around the world are intensifying 
efforts to deliver higher value care. Reducing 
preventable hospital visits has drawn policy attention 
as an opportunity to improve quality of care and 
reduce healthcare spending in several countries, 
including the United States, England, Denmark, and 
Germany.1 In the US, the Centers for Medicare and 
Medicaid Services (CMS) has implemented national 
initiatives that aim to push clinicians and hospitals 
to reduce readmissions for Medicare fee-for-service 
patients over the age of 65. In 2009, for example, CMS 
began publicly reporting 30 day readmission rates as 
a measure of hospital performance. One year later, the 
Hospital Readmissions Reduction Program (HRRP) 
was established, mandating that CMS impose financial 
penalties on acute care hospitals in the US with higher 
than expected 30 day readmission rates after a hospital 
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WhAt Is AlreAdy knoWn on thIs topIc
Readmission rates at 30 days are increasingly used to measure quality of care 
and evaluate provider and hospital performance under value based payment 
programs in the United States
Readmission rates for medical conditions targeted by one such program, the 
Hospital Readmissions Reduction Program (heart failure, acute myocardial 
infarction, and pneumonia), have declined modestly on a national scale
Policymakers have attributed these reductions to improved discharge planning, 
care transitions, and post-discharge care after index hospital stays, but these 
declines could be because clinicians and hospitals have increasingly adopted 
strategies to manage patients who return to a hospital within 30 days of 
discharge in emergency departments or as observation stays—which are not 
included in the current readmission measure
WhAt thIs study Adds
Total hospital revisits within 30 days of discharge after a hospital admission for 
target conditions have steadily increased under the HRRP, due to a rise in treat-
and-discharge visits in an emergency department and observation stays
Although reductions in readmissions have been attributed to improvements 
in discharge planning and transitional care, as intended by the HRRP, these 
declines instead appear to be due to intensified efforts to manage patients who 
return within 30 days of discharge in emergency departments and observation 
units
A metric to measure patients’ 30 day return to hospital that captures all post-
discharge encounters (inpatient, emergency department, and observation stays) 
could provide a more comprehensive, accurate, and fair assessment of hospital 
quality and performance
by copyright.  on 4 S
eptem















J: first published as 10.1136/bm






2 doi: 10.1136/bmj.l4563 | BMJ 2019;366:l4563 | the bmj
stay for common medical conditions. Penalties under 
the HRRP began in 2012 and are capped at 3% of 
Medicare payments to hospitals; 82% of hospitals 
were penalized in fiscal year 2019.2
Readmissions alone, however, do not capture the 
full spectrum of hospital revisits that can occur after 
discharge. A return visit to an emergency department, 
even if it does not result in an inpatient hospital 
stay, might also reflect inadequate care transitions 
or fragmented post-discharge care. In addition, 
observation stays, which are short hospital stays that 
are reimbursed differently from full inpatient hospital 
stays, are increasingly being used in the US as an 
alternative to inpatient hospital stays, and can occur 
in an emergency department, hospital observation 
unit, or a typical inpatient ward setting.3 However, 
neither of these encounters (emergency department 
or observation stays) are included as outcomes in the 
30 day readmission measure used by CMS to evaluate 
hospital care quality under the HRRP.4
Understanding nationwide trends in total hospital 
based encounters (including treat-and-discharge visits 
to an emergency department, observation stays, or 
inpatient readmissions) within 30 days of discharge, 
for conditions targeted by the HRRP, is critically 
important from a policy perspective. A reduction in 
total revisits would suggest widespread improvements 
in discharge planning and transitions of care during 
hospital stays, as well as care coordination and quality 
in the post-discharge period, as intended by the HRRP. 
By contrast, if hospital revisits after discharge have 
not changed, or have increased, previously observed 
reductions in readmissions5 might simply reflect greater 
management of patients in emergency departments 
and observation units, and the readmission measure 
currently used by CMS could provide an incomplete 
picture of hospital performance. Therefore, in this 
study, we aimed to answer three policy relevant 
questions:
•	 Have total hospital revisits within 30 days of 
discharge after a hospital stay for medical conditions 
targeted by the HRRP changed over time? 
•	 How have rates of treat-and-discharge visits to an 
emergency department, observation stays (not 
leading to readmission), and readmissions each 
contributed to changes in total hospital revisits? 
•	 Do these patterns differ if all 30 day post-discharge 
revisits per patient are counted, to provide a more 
comprehensive assessment of hospital use after 
discharge, rather than just the first revisit as done 
by CMS for the readmission measure?
Methods
study cohort
We used Medicare Provider Analysis and Review files 
to identify index hospital stays at acute care hospitals 
from 1 January 2012 to 1 October 2015 with a principal 
discharge diagnosis of heart failure, acute myocardial 
infarction, or pneumonia—medical conditions targeted 
by the HRRP. We defined study cohorts using ICD-9-CM 
(international classification of diseases, 9th revision, 
clinical modification) codes used in the publicly 
reported CMS readmission and mortality measures. 
We included Medicare beneficiaries aged 65 or older 
who were alive at discharge, and excluded patients 
who were discharged against medical advice, were 
not enrolled in Medicare fee for service for at least 30 
days after discharge (absent death), or were enrolled 
in Medicare fee for service for less than one year before 
hospital admission. Transfers to other hospitals were 
linked to one index hospital stay.6 Comorbidities were 
defined by hierarchical condition categories based 
on inpatient Medicare claims up to one year before 
hospital admission, and diagnosis codes per claim 
were limited to the first nine codes,7 as has been done 
in previous studies.5 6 8 9 We used outpatient claims 
files and previously described methods to identify 
observation stays10 as well as treat-and-discharge 
visits to an emergency department3 that occurred 
within 30 days of discharge after the index hospital 
stay.
Outcomes
Our primary outcome was the trend in total hospital 
revisits within 30 days of discharge after a hospital stay 
for medical conditions targeted by the HRRP. We also 
evaluated revisits by type: treat-and-discharge visits to 
an emergency department, observation stays (not later 
leading to readmission), and readmissions. For each 
revisit, we used two different approaches: we counted 
only one revisit (the first event after discharge) for each 
type of encounter after the index hospital stay, as CMS 
does for the readmission measure4; and we counted all 
revisits within 30 days of discharge.
statistical analysis
Logistic regression was used to fit a model for the 
outcome of the first post-discharge revisit among 
patients surviving up to discharge. We used a Poisson 
regression model for the outcome of all revisits. 
Models included reason for the index hospital stay 
(eg, heart failure, acute myocardial infarction, or 
pneumonia), demographics (age, sex, race), and 
clinical comorbidities as independent variables. After 
constructing separate models for each month (45 
models for 45 months), we estimated the mean of the 
potential outcomes for each respective month using 
the demographics and clinical comorbidity profiles of 
patients admitted to hospital in 2014 as a reference, 
which was the most recent year that contained 12 
calendar months of data. A smoothing spline was then 
fitted to the 45 data points to show temporal trends. 
A simple linear regression was also fitted to the 45 
data points to estimate the monthly change for each 
type of revisit per 100 patient discharges. We then 
repeated this analysis to evaluate trends in revisits by 
patient subgroups. Additional details regarding the 
methodological approach and inferential strategy are 
provided in the supplement. Analyses were performed 
with SAS version 9.4 (SAS Institute). Institutional 
review board approval, including waiver of the 
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requirement of participant informed consent because 
the data were deidentified, was provided by the Beth 
Israel Deaconess Medical Center.
Patient and public involvement
Patients and the public were not involved in planning, 
design, or interpretation of the study. The study 
involved examination of existing claims data and 
no participants were recruited for this analysis. We 
intend to engage patients and health policymakers by 
disseminating this research through press releases, 
blog posts, and at research meetings. This research 
was done without patient involvement. Patients were 
not invited to comment on the study design and were 
not consulted to develop patient relevant outcomes 
or interpret the results. Patients were not invited to 
contribute to the writing or editing of this document 
for readability or accuracy.
results
Our study cohort included 3 038 740 total index 
hospital stays from January 2012 to September 
2015: 1 357 620 for heart failure, 634 795 for 
acute myocardial infarction, and 1 046 325 for 
pneumonia. Baseline characteristics for all index 
hospital stays are shown in eTable 1. Over the study 
period, 840 114 hospital revisits within 30 days of 
discharge (counting only the first revisit of any type 
after discharge) occurred, including 265 055 treat-
and-discharge visits to an emergency department, 
80 083 observation stays, and 599 664 inpatient 
readmissions (counting only the first revisit for 
each type of encounter). After counting all revisits 
after the index hospital stays, we found 1 064 410 
total hospital revisits, of which 303 194 were treat-
and-discharge visits to an emergency department, 
84 169 were observation stays, and 677 047 were 
readmissions (eTable 2).
The number of first hospital revisits per 100 
patient discharges for medical conditions targeted 
by the HRRP increased during the study (monthly 
change 0.016 revisits per 100 patient discharges 
(95% confidence interval 0.006 to 0.026); table 1). 
This change was driven by an increase in treat-and-
discharge visits to an emergency department (0.022 
(0.014 to 0.029)) and observation stays (0.022 
(0.019 to 0.024)), which were only partly offset by 
reductions in inpatient readmissions (−0.013 (−0.023 
to −0.002)).
These changes became more pronounced after 
we counted all revisits per patient within 30 days 
of discharge. The monthly change in total hospital 
revisits per 100 patient discharges increased (0.023 
(95% confidence interval 0.010 to 0.035)), due to 
a rise in treat-and-discharge visits to an emergency 
department (0.023 (0.015 to 0.032)) and observation 
stays (0.022 (0.020 to 0.025)), while readmissions 
decreased (−0.023 (–0.035 to −0.012)). Figure 1 shows 
spline fitted trends of hospital revisits across all target 
conditions, and eFigures 1-2 show trends by individual 
target condition.
Patient subgroups (age, sex, and race) were also 
evaluated, as shown in table 2. Counting all revisits per 
patient, the monthly change in total hospital revisits 
per 100 patient discharges did not differ significantly 
among patients younger than 80 compared with 
patients aged 80 and over. Trends in treat-and-
discharge visits to an emergency department, 
observation stays, and readmissions also did not 
differ between these age groups. In addition, we saw 
no significant difference in revisit trends among men 
compared to women. The monthly change in total 
hospital revisits and in treat-and-discharge visits to 
an emergency department were also similar among 
white patients compared with non-white patients. 
However, increases in observation stays within 30 days 
of discharge were more pronounced among non-white 
patients than white patients (monthly change 0.029 
stays per 100 patient discharges (95% confidence 
interval 0.024 to 0.034) v 0.021 (0.018 to 0.024); 
P=0.006 for difference).
Overall, we observed no significant changes in 
mortality within 30 days of discharge across the three 
targeted conditions (−0.0034 (95% confidence interval 
−0.012 to 0.0054)) from 2012 to 2015. Post-discharge 
mortality at 30 days did not change among patients 
admitted to hospital for heart failure (0.00 (−0.011 to 
0.010)), acute myocardial infarction (−0.006 (−0.015 
to 0.002)), or pneumonia (−0.004 (−0.013 to 0.005); 
fig 2 and eTable 3).
table 1 | risk standardized monthly change in hospital revisits, treat-and-discharge visits to an emergency department, 
observation stays, and readmissions within 30 days of discharge for medical conditions targeted by the HrrP in the us
Monthly change in no of revisits per 100 patient discharges (95% ci)
First revisit*
Any hospital revisit +0.016 (0.006 to 0.026)
Treat-and-discharge visit to emergency department +0.022 (0.014 to 0.029)
Observation stay +0.022 (0.019 to 0.024)
Readmission −0.013 (−0.023 to −0.002)
all revisits†
Any hospital revisit +0.023 (0.010 to 0.035)
Treat-and-discharge visit to emergency department +0.023 (0.015 to 0.032)
Observation stay +0.022 (0.020 to 0.025)
Readmission −0.023 (−0.035 to −0.012)
Data based on Medicare fee-for-service patients aged 65 or over between 1 January 2012 and 1 October 2015. Target conditions include heart failure, 
acute myocardial infarction, or pneumonia.
*Among patients with multiple hospital revisits within 30 days of discharge, only the first revisit for each type of encounter was counted.
†Among patients with multiple hospital revisits within 30 days of discharge, all visits for each type of encounter were counted.
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discussion
In this study of Medicare beneficiaries admitted to 
hospital for heart failure, acute myocardial infarction, 
and pneumonia in the US between 2012 and 2015, 
we found an increase in total hospital revisits within 
30 days of discharge despite a reduction in 30 day 
readmissions. This increase was because of a rise in 
treat-and-discharge visits to an emergency department 
and observation stays within 30 days of discharge, 
which on national level, exceeded the decline in 
readmissions. Our finding of increased healthcare 
use during this period was more pronounced after we 
included all encounters within 30 days of discharge 
from the index hospital stay—rather than simply 
including the first revisit.
In the US, nationwide reductions in readmission 
rates for medical conditions targeted by the HRRP have 
been viewed as markers of improvements in quality of 
care. Our findings suggest that this success could be 
illusory because total hospital revisits after discharge 
are, in fact, rising. If reductions in readmissions 
were being driven by widespread improvements 
in discharge planning, care transitions and post-
discharge care after a hospital stay (as intended by 
the HRRP), total hospital revisits within 30 days of 
discharge would also be expected to decline. Instead, 
much of the reduction in readmissions seems to reflect 
intensified efforts to manage patients who return to 
a hospital after discharge in observation units and 
emergency departments, potentially because the 30 
day readmission measure used to evaluate hospital 
performance under the HRRP does not include these 
types of post-discharge encounters. These observations 
perhaps explain why previous studies have shown that 
inpatient quality of care delivered to patients admitted 
to hospital for heart failure or acute myocardial 
infarction do not differ at hospitals with high versus 
low readmission rates.11 12
The increase in use of observation stays and 
emergency department visits (compared with inpatient 
hospital stays) among patients who return after 
discharge could be a good thing if it reflects that patients 
are, on average, returning with lower severity illness 
that can be safely managed in a non-admission setting. 
These revisits could also be beneficial to patient care. 
For instance, observation stays have been associated 
with higher patient satisfaction than inpatient hospital 
stays,13 although they can also result in higher out-of-
pocket expenditures and more financial hardship for 
patients than inpatient hospital stays.14 15
However, the increasing use of emergency 
department visits for post-discharge care could be 
problematic. Data have suggested that hospitals that 
tend to manage patients in emergency departments 
rather than admitting them for an inpatient stay 
have higher rates of early death after discharge.16 We 
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Fig 1 | risk standardized hospital revisits, treat-and-discharge visits to an emergency department, observation stays, and readmissions within 30 
days of discharge for medical conditions targeted by the HrrP in the us. spline fitted trends of hospital revisits are shown for all target conditions 
(heart failure, acute myocardial infarction, or pneumonia). Data based on Medicare fee-for-service patients aged 65 or over between 1 january 2012 
and 1 October 2015. Yellow line=trends including only the first revisit for each type of encounter (eg, any hospital revisit, treat-and-discharge visit 
to an emergency department, observation stay, or inpatient readmission); purple line=trends including all revisits for each type of encounter
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observed no change in post-discharge mortality at 30 
days for target conditions during the HRRP (from 2012 
to 2015). However, several independent analyses 
have found that the implementation of the HRRP was 
associated with an increase in post-discharge mortality 
at 30 days among patients admitted for heart failure 
and pneumonia compared with pre-HRRP trends (pre-
2010), and that this increase was concentrated entirely 
among patients not readmitted after discharge.6 17-
19 Whether intensified efforts to manage returning 
patients in emergency departments and observation 
units explain increases in mortality observed in the 
years that preceded our study period is an important 
area for further research, given that this potential 
mechanism could explain increased mortality under 
the HRRP.20-24
Policy implications
Our findings have important policy implications for 
value based programs that use the 30 day readmission 
measure to evaluate hospital and provider care quality. 
Firstly, focusing on 30 day readmissions while ignoring 
other types of hospital revisits overestimates the 
clinical and financial benefits of incentives to reduce 
readmissions. Secondly, use of 30 day readmissions as 
the sole quality metric could impede fair comparisons 
of hospital performance, particularly given wide 
variation in triage patterns in emergency departments 
and the availability and use of observation units.25 
Finally, given these limitations, the 30 day readmission 
rate seems to be an inappropriate target for financial 
incentives for hospitals (as used in the HRRP) or 
outpatient practices (as being increasingly used in 
pay-for-performance programs). Measuring all revisits 
within 30 days of discharge (that is, a “30 day return 
to hospital” metric) could instead provide a more 
comprehensive, accurate, and fair assessment of 
provider and hospital care quality.26
Several countries, including England, Germany, and 
Denmark, have implemented national level policies 
that aim to reduce readmissions, and others are 
actively considering similar initiatives.27 In England, 
incentives to reduce all cause readmissions were 
announced in 2010,28 and from fiscal years 2011-12, 
hospitals were no longer reimbursed for readmissions 
within 30 days of discharge exceeding a locally set 
threshold. However, the extent to which reductions in 
readmissions in England are due to improved quality 
of care during the index hospital stay, or instead, are 
due to greater management and treatment of patients 
who return after discharge in emergency departments 
is unknown. This area is important for future study, 
particularly given growing concern in the US that a 
focus on reducing readmissions could have adversely 
affected patients at the margin who would have 
benefited from inpatient level care.
strengths and limitations of this study
Our study had limitations. We did not examine 
whether the increase in total hospital revisits, and 
emergency department visits and observation stays 
in particular, was associated with changes in patient 
satisfaction, or changes in Medicare spending and 
beneficiary out-of-pocket expenditures. We were also 
unable to evaluate whether greater shifts in emergency 
department and observation use occurred in the years 
before our study, when the HRRP was announced in 
2010, and if this affected patient experience, quality 
of care, and mortality. This area remains important for 
future research given ongoing discussions regarding 
the potential unintended consequences of this 
program.21-23 26 29-31
conclusions
Although readmissions for target conditions decreased 
from 2012 to 2015 in the US, total hospital revisits 
within 30 days of discharge steadily increased over that 
same period. This increase was due to a rise in treat-
and-discharge encounters in emergency departments 
and observation stays, which on a national level, 
exceeded the decline in readmissions over the same 
table 2 | risk standardized monthly change in hospital revisits, treat-and-discharge 
visits to an emergency department (eD), observation stays, and readmissions within 30 
days of discharge for medical conditions targeted by the HrrP in the us, categorized by 
patient subgroups
Patient characteristic
Monthly change in no of revisits per 100 patient dis-
charges (95% ci) P*
comparator group 1 comparator group 2
age (<80 v ≥80 years)
First revisit† 
 Any hospital revisit +0.016 (0.007 to 0.027) +0.015 (0.004 to 0.026) 0.89
 ED treat-and-discharge visit +0.024 (0.016 to 0.032) +0.019 (0.012 to 0.027) 0.36
 Observation stay +0.023 (0.020 to 0.026) +0.021 (0.018 to 0.023) 0.30
 Readmission −0.014 (−0.025 to −0.003) −0.012 (−0.023 to 0.00) 0.80
All revisits‡
 Total hospital revisits +0.030 (0.015 to 0.045) +0.015 (0.012 to 0.028) 0.08
 ED treat-and-discharge visit +0.027 (0.017 to 0.037) +0.020 (0.011 to 0.029) 0.29
 Observation stay +0.024 (0.021 to 0.027) +0.020 (0.017 to 0.024) 0.08
 Readmission −0.021 (−0.034 to −0.009) −0.026 (−0.038 to −0.014) 0.56
sex (men v women)
First revisit† 
 Any hospital revisit +0.016 (0.006 to 0.026) +0.016 (0.005 to 0.027) 1.00
 ED treat-and-discharge visit +0.022 (0.015 to 0.029) +0.021 (0.014 to 0.029) 0.84
 Observation stay +0.023 (0.021 to 0.025) +0.020 (0.017 to 0.024) 0.13
 Readmission −0.013 (−0.025 to −0.001) −0.012 (−0.023 to −0.002) 0.90
All revisits‡
 Total hospital revisits +0.024 (0.012 to 0.037) +0.021 (0.006 to 0.035) 0.75
 ED treat-and-discharge visit +0.024 (0.015 to 0.034) +0.023 (0.013 to 0.032) 0.88
 Observation stay _+0.024 (0.022 to 0.027) +0.021 (0.017 to 0.025) 0.20
 Readmission −0.024 (−0.037 to −0.012) −0.023 (−0.034 to −0.011) 0.91
race (white v non-white)
First revisit† 
 Any hospital revisit +0.017 (0.008 to 0.027) +0.009 (−0.005 to 0.023) 0.36
 ED treat-and-discharge visit +0.022 (0.015 to 0.029) +0.020 (0.011 to 0.028) 0.71
 Observation stay +0.021 (0.018 to 0.023) +0.027 (0.023 to 0.031) 0.01
 Readmission −0.011 (−0.022 to −0.001) −0.021 (−0.035 to −0.007) 0.26
All revisits‡
 Total hospital revisits +0.023 (0.011 to 0.035) +0.021 (0.001 to 0.043) 0.87
 ED treat-and-discharge visit +0.023 (0.014 to 0.033) +0.024 (0.013 to 0.035) 0.89
 Observation stay +0.021 (0.018 to 0.024) +0.029 (0.024 to 0.034) 0.006
 Readmission −0.022 (−0.033 to −0.011) −0.031 (−0.048 to −0.014) 0.37
Data based on Medicare fee-for-service patients aged 65 or over between 1 January 2012 and 1 October 2015. 
Target conditions include heart failure, acute myocardial infarction, or pneumonia.
*P value for difference in monthly change among subgroups.
†Among patients with multiple hospital revisits within 30 days of discharge, only the first revisit for each type of 
encounter was counted.
‡Among patients with multiple hospital revisits within 30 days of discharge, all visits for each type of encounter 
were counted.
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period. Given that total hospital revisits are rising, 
nationwide reductions in readmissions could reflect 
intensified efforts to manage patients who return to 
a hospital after discharge to emergency departments 
and observation units rather than improvements in 
discharge planning and care transitions during index 
hospital stays, as intended by the HRRP. Future policy 
efforts in the US could benefit from measuring total 
hospital revisits within 30 days of discharge instead 
of solely focusing on readmissions, to strengthen 
incentives to improve quality of care and provide a 
more comprehensive assessment of care quality and 
healthcare use in the post-discharge period.
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